Quantcast

Latest treatment of HIV Stories

2014-09-08 08:29:30

Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another RICHMOND, Calif., Sept. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, resulted in sustained reduction and control of viral load (VL) in the absence of antiretroviral drugs...

2011-05-20 10:27:00

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral...

2011-03-03 06:00:00

RICHMOND, Calif., March 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston from February 27 to March 2, 2011. "SB-728-T is a key addition to the toolbox of technologies required to move from the bone marrow transplant setting...

2011-03-02 15:05:00

BOSTON, March 2, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial. Data for AGS-004 were presented in a poster at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. In the study, AGS-004 was safe and well...

2011-02-28 07:30:00

RICHMOND, Calif., Feb. 28, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of positive preliminary clinical data from its Phase 1 trial (SB-728-902). The trial is being conducted in immunologic non-responders, HIV-infected subjects who are currently on highly active antiretroviral therapy (HAART) and have undetectable levels of virus but suboptimal CD4+ T-cell counts. The study is designed to evaluate safety and clinical outcomes of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'